The Mirena® levonorgestrel system

Drugs of Today

Volumn 39, Issue 12, 2003, Pages 973-984

  McGavigan, C Jay ^a   Cameron, Iain T ^b  

^a SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; TAMOXIFEN; CONTRACEPTIVE AGENT;

ADENOMYOSIS; AMENORRHEA; BLEEDING; BREAKTHROUGH BLEEDING; CONTRACEPTION; ENDOMETRIOSIS; FEMALE; GYNECOLOGIC DISEASE; HISTOPATHOLOGY; HORMONAL THERAPY; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; LEIOMYOMATOSIS; LONG TERM CARE; MENORRHAGIA; MENSTRUAL CYCLE; OVARY INSUFFICIENCY; PATIENT COMPLIANCE; PATIENT COUNSELING; PROGESTERONE METABOLISM; REVIEW; VASCULARIZATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ENDOMETRIUM; INTRAUTERINE CONTRACEPTIVE DEVICE; MULTICENTER STUDY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; ULTRASTRUCTURE;

CONTRACEPTIVE AGENTS, FEMALE; ENDOMETRIUM; FEMALE; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS;

EID: 2342666211     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2003.39.12.799415     Document Type: Review

References (71)

1. Hubacher, D., Grimes, D.A. Noncontraceptive health benefits of intrauterine devices: A systematic review. Obstet Gynecol Surv 2002, 57: 120-8.
2. Backman, T., Huhtala, S., Blom, T., Luoto, R., Rauramo, I., Koskenvuo, M. Length of use and symptoms associated with premature removal of the levonorgestrel intrauterine system: A nation-wide study of 17,360 users. Brit J Obstet Gynaecol 2000, 107: 335-9.
3. Ismail, H., Mansour, D.J.A. Acceptability and efficacy of copper intrauterine devices and the levonorgestrel intrauterine system used in a family planning setting from 1995-1998. Poster, Annual General Meeting, Faculty of Family Planning and Reproductive Health Care, May 2001.
4. Sivin, I., Stern, J., Coutinho, E. et al. Prolonged intrauterine contraception: A seven-year randomized study of the levonorgestrel 20 mcg/day (LNg20) and the Copper T380 Ag IUDs. Contraception 1991, 44: 473-80.
5. Andersson, K., Odlind, V., Rybo, G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: A randomized comparative trial. Contraception 1994, 49: 56-72.
6. Merki-Feld, G.S., Lebeda, E., Hogg, B., Keller, P.J. The incidence of actinomyces-like organisms in Papanicolaou-stained smears of copper-and levonorgestrel-releasing intrauterine devices. Contraception 2000, 61: 365-8.
7. Andersson, K., Rybo, G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Brit J Obstet Gynaecol 1990, 97: 690-4.
8. Andersson, K., Mattsson, L.A., Rybo, G., Stadberg, E. Intrauterine release of levonorgestrel - A new way of adding progestogen in hormone replacement therapy. Obstet Gynecol 1992, 79: 963-7.
9. Suhonen, S.P., Allonen, H.O., Lahteenmaki, P. Sustained-release estradiol implants and a levonorgestrel-releasing intrauterine device in hormone replacement therapy. Amer J Obstet Gynecol 1995, 172: 562-7.
10. Suhonen, S., Holmstrom, T., Lahteenmaki, P. Three-year follow-up of the use of a levonorgestrel-releasing intrauterine system in hormone replacement therapy. Acta Obstet Gynecol Scand 1997, 76: 145-50.
11. Suvanto-Luukkonen, E., Kauppila, A. The levonorgestrel intrauterine system in menopausal hormone replacement therapy: Five-year experience. Fert Ster 1999, 72: 161-3.
12. Wollter-Svensson, L.O., Stadberg, E., Andersson, K., Mattsson, L.A., Odlind, V., Persson, I. Intrauterine administration of levonorgestrel 5 and 10 microg/24 hours in perimenopausal hormone replacement therapy. A randomized clinical study during one year. Acta Obstet Gynecol Scand 2002, 76: 449-54.
13. Ronnerdag, M., Odlind, V. Health effects of long-term use of the intrauterine levonorgestrel-releasing system-A follow-up study over 12 years of continuous use. Acta Obstet Gynecol Scand 1999, 78: 716-21.
14. Sivin, I., Stern, J., Diaz, J. et al. Two years of intrauterine contraception with levonorgestrel and with copper: A randomized comparison of the T Cu 380Ag and levonorgestrel 20 mcg/day devices. Contraception 1987, 35: 245-55.
15. Barbosa, I., Bakos, O., Olsson, S.-E., Odlind, V., Johansson, E.D.B. Ovarian function during use of a levonorgestrel-releasing IUD. Contraception 1990, 42: 51-66.
16. Lahteenmaki, P., Allonen, H., Kulmala, Y. Endocervical cytological smear abnormalities (Papanicolaou class III-IV) during use of levonorgestrel IUD and copper-IUD (Nova T). Leiras Study Report 1206, 1991.
17. Silverberg, S.G., Haukkamaa, M., Arko, H., Nilsson, C.G., Luukkainen, T. Endometrial morphology during long-term use of levonorgestrel-releasing intrauterine devices. Intern J Gynecol Pathol 1986, 5: 235-41.
18. Nilsson, C.G., Lahteenmaki, P., Arko, H. Endometrial morphology of women using a D-norgestrel-releasing intrauterine device. Fert Ster 1978, 29: 397-401.
19. Pakarinen, P., Luukkainen, T., Laine, H., Lahteenmaki, P. The effect of local intrauterine levonorgestrel administration on endometrial thickness and uterine blood circulation. Human Reprod 1995, 10: 2390-4.
20. Zhu, P., Liu, X., Luo, H. et al. The effect of a levonorgestrel-releasing intrauterine device on human endometrial oestrogen and progesterone receptors after one year of use. Human Reprod 1999, 14, 970-5.
21. Critchley, H.O., Wang, H., Kelly, R.W., Gebbie, A.E., Glasier, A.F. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system. Human Reprod 1998, 13: 1210-7.
22. Gu, Z., Zhu, P., Luo, H., Zhu, X., Zhang, G., Wu, S. A morphometric study on the endometrial activity of women before and after one year with LNG-IUD in situ. Contraception 1995, 52: 57-61.
23. McGavigan, C.J., Dockery, P., Metaxa-Mariatou, V. et al. Hormonally mediated disturbance of angiogenesis in the human endometrium after exposure to intrauterine levonorgestrel. Human Reprod 2003, 18: 77-84.
24. Pakarinen, P.I., Lahteenmaki, P., Lehtonen, E., Reima, I. The ultrastructure of human endometrium is altered by administration of intrauterine levonorgestrel. Human Reprod 1998, 13: 1846-53.
25. Maruo, T., Laoag-Fernández, J.B., Pakarinen, P., Murakoshi, H., Spitz, I.M., Johansson, E. Effects of the levonorgestrel-releasing intrauterine system on proliferation and apoptosis in the endometrium. Human Reprod 2001, 16: 2103-8.
26. Hynes, R.O. Integrins: A family of cell surface receptors. Cell 1987, 48: 549-54.
27. Lessey, B.A., Castelbaum, A.J., Buck, C.A., Lei, Y., Yowell, C.W., Sun, J. Integrin adhesion molecules in the human endometrium. Correlation with the normal and abnormal menstrual cycle. J Clin Invest 1992, 90: 188-95.
28. Ruoslahti, E. Integrins. J Clin Invest 1991, 87: 1-5.
29. Tabibzadeh, S., Babaknia, A. The signals and molecular pathways involved in implantation, a symbiotic interaction between blastocyst and endometrium involving adhesion and tissue invasion. Molec Human Reprod 1995, 1: 1579-1602.
30. Rodgers, W.H., Osteen, K.G., Matrisian, L.M., Navbre, M., Guidice, L.C., Gorstein, F. Expression and localization of matrilysin, a matrix metalloproteinase in human endometrium during the reproductive cycle. Amer J Obstet Gynecol 1992, 168: 253-60.
31. Rodgers, W.H., Matrisian, L.M., Giudice, L.C. et al. Patterns of matrix metalloproteinase expression in cycling endometrium imply differential functions and regulation by steroid hormones. J Clin Invest 1994, 94, 946-53.
32. Hampton, A.L., Salamonsen, L.A. Expression of messenger ribonucleic acid encoding matrix metalloproteinases and their tissue inhibitors is related to menstruation. J Endocrinol 1994, 141: R1-3.
33. Osteen, K.G., Rodgers, W.H., Gaire, M., Hargrove, J.T., Gorstein, F., Matrisian, L.M. Stromal-epithelial interaction mediates steroidal regulation of metalloproteinase expression in human endometrium. Proceed Nat Acad Sci USA 1994, 91: 10129-33.
34. Schatz, F., Aigner, S., Papp, C., Toth Pal, E., Lockwood, C.J. Ovarian steroid-modulated stromelysin-1 expression in human endometrial stromal and decidual cells. J Clin Endocrinol Metab 1994, 78: 1467-72.
35. Clark, D.A., Daya, S. Macrophages and other migratory white cells in the endometrium; relevance to endometrial bleeding. In: Contraception and Mechanisms of Endometrial Bleeding. d'Arcangues, C., Fraser, I.S., Newton, J.R., Odlind, V. (Eds.). Cambridge University Press 1990, 363-83.
36. Milne, S.A., Rakhyoot, A., Drudy, T.A., Brechin, S., Riley, S.C., Critchley, H.O.D. Co-localization of matrix metalloproteinase-1 and mast cell tryptase in the human uterus. Molec Human Reprod 2001, 7: 559-65.
37. Critchley, H.O., Wang, H., Jones, R.L. et al. Morphological and functional features of endometrial decidualization following long-term intrauterine levonorgestrel delivery. Human Reprod 1998, 13: 1218-24.
38. Perino, A., Quartararo, P., Catinella, E., Genova, G., Cittadini, E. Treatment of endometrial hyperplasia with levonorgestrel releasing intrauterine devices. Acta Europ Fert 1987, 18: 137-40.
39. Zhu, P.D., Luo, H.Z., Xu, R.H. et al. The effect of intrauterine devices, the stainless steel ring, the copper T220, and releasing levonorgestrel, on the bleeding profile and the morphological structure of the human endometrium - A comparative study of three IUDs. A morphometric study of 96 cases. Contraception 1989, 40: 425-38.
40. Laoag-Fernández, J.B., Maruo, T., Pakarinen, P., Spitz, I.M., Johansson, E. Effects of levonorgestrel-releasing intra-uterine system on the expression of vascular endothelial growth factor and adrenomedullin in the endometrium in adenomyosis. Human Reprod 2003, 18: 694-9.
41. Nilsson, C.G., Lahteenmaki, P.L., Luukkainen, T., Robertson, D.N. Sustained intrauterine release of levonorgestrel over five years. Fert Ster 1986, 45: 805-7.
42. Pakarinen, P.I., Suvisaari, J., Luukkainen, T., Lahteenmaki, P. Intracervical and fundal administration of levonorgestrel for contraception: Endometrial thickness, patterns of bleeding, and persisting ovarian follicles. Fert Ster 1997, 68: 59-64.
43. Peterson, H.B., Xia, Z., Hughes, J.M. et al. The risk of pregnancy after tubal sterilization: Findings from the U.S. Collaborative Review of Sterilization. Amer J Obstet Gynecol 1996, 174: 1161-70.
44. French, R.S., Cowan, F.M., Mansour, D. et al. Levonorgestrel-releasing (20 microgram/day) intrauterine systems (Mirena) compared with other methods of reversible contraceptives. Brit J Obstet Gynaecol 2000, 107: 1218-25.
45. Barrington, J.W., Bowen-Simpkins, P. The levonorgestrel intrauterine system in the management of menorrhagia. Brit J Obstet Gynaecol 1997, 104: 614-6.
46. Crosignani, P.G., Vercellini, P., Mosconi, P., Oldani, S., Cortesi, de Giorgi, O. Levonorgestrel-releasing intrauterine device versus hysteroscopic endometrial resection in the treatment of dysfunctional uterine bleeding. Obstet Gynecol 1997, 90: 257-63.
47. Irvine, G.A., Campbell-Brown, M.B., Lumsden, M.A., Heikkila, A., Walker, J.J., Cameron, I.T. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Brit J Obstet Gynaecol 1998, 105: 592-8.
48. Istre, O., Trolle, B. Treatment of menorrhagia with the levonorgestrel intrauterine system versus endometrial resection. Fert Ster 2001, 76: 304-9.
49. Lahteenmaki, P., Haukkamaa, M., Puolakka, J. Open randomised study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy. Brit Med J 1998, 316: 1122-6.
50. Milsom, I., Andersson, K., Andersch, B., Rybo, G. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Amer J Obstet Gynecol 1991, 164: 879-83.
51. Romer, T. Prospective comparison study of levonorgestrel IUD versus Roller-Ball endometrial ablation in the management of refractory recurrent hypermenorrhea. Eur J Obstet Gynecol Reprod Biol 2000, 90: 27-9.
52. Tang, G.W., Lo, S.S. Levonorgestrel intrauterine device in the treatment of menorrhagia in Chinese women: Efficacy versus acceptability. Contraception 1995, 51: 231-5.
53. Parkin, D.E. Surgical techniques for the treatment of dysfunctional uterine bleeding. In: Disorders of the Menstrual Cycle. O'Brien, S., Cameron, I., MacLean, A. (Eds.). RCOG Press, London 2000, 241-51.
54. O'Donovan, P., McGurgan, P., Prendiville, W. (Eds.). Conservative surgery for menorrhagia. Greenwich Medical Media Ltd., London 2003.
55. Hurskainen, R., Teperi, J., Rissanen, P. et al. Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: A randomised trial. Lancet 2001, 357: 273-7.
56. Raudaskoski, T., Lahti, E., Kauppila, A., Apaja-Sarkkinen, M., Laatikainen, T. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: Clinical and endometrial responses. Amer J Obstet Gynecol 1995, 172: 114-9.
57. Suvanto-Luukkonen, E., Sundstrom, H., Penttinen, J., Laara, E., Pramila, S., Kauppila, A. Percutaneous estradiol gel with an intrauterine levonorgestrel releasing device or natural progesterone in hormone replacement therapy. Maturitas 1997, 26: 211-7.
58. Gardner, F.J.E., Konje, J.C., Abrams, K.R. et al. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: A randomised controlled trial. Lancet 2000, 356: 1711-7.
59. Vercellini, P., Aimi, G., Panazza, S., de Giorgi, O., Pesole, A., Crosignani, P.G. A levonorgestrel-releasing intrauterine system for the treatment of dysmenorrhea associated with endometriosis: A pilot study. Fert Ster 1999, 72: 505-8.
60. Fedele, L., Bianchi, S., Raffaelli, R., Portuese, A., Dorta, M. Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device. Fert Ster 1997, 68: 426-9.
61. Fong, Y.F., Singh, K. Medical treatment of a grossly enlarged adenomyotic uterus with the levonorgestrel-releasing intrauterine system. Contraception 1999, 60: 173-5.
62. Rybo, G., Lenman, J., Tibbin, R. Epidemiology of menstrual blood loss. In: Baird, D.T., Michie, E.A. (Eds.). Mechanisms of Menstrual Bleeding. Raven Press, New York 1985, 181-93.
63. Kawaguchi, K., Fujii, S., Konishi, I., Okamura, H., Mori, T. Ultrastructural study of cultured smooth muscle cells from uterine leiomyoma and myometrium under the influence of sex steroids. Gynecol Oncol 1985, 21: 32-41.
64. Friedman, A.J., Barbieri, R.L., Doubilet, P.M., Fine, C., Schiff, I. A randomized, double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri. Fert Ster 1988, 49: 404-9.
65. Sivin, I., Stern, J. Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: A multicenter study. Fert Ster 1994, 61: 70-7.
66. Lumbiganon, P., Rugpao, S., Phandhu-fung, S., Laopaiboon, M., Vudhikamraksa, N., Werawatakul, Y. Protective effect of depot-medroxyprogesterone acetate on surgically treated uterine leiomyomas: A multicentre case-control study. Brit J Obstet Gynaecol 1996, 103: 909-14.
67. Fayed, Y.M., Tsibris, J.C., Langenberg, P.W., Robertson, A.L. Jr. Human uterine leiomyoma cells: Binding and growth responses to epidermal growth factor, platelet-derived growth factor and insulin. Labor Invest 1989, 60: 30-7.
68. Fong, Y.F., Singh, K. Effect of the levonorgestrel-releasing intrauterine system on uterine myomas in a renal transplant patient. Contraception 1999, 60: 51-3.
69. Ikomi, A., Pepra, E.F. Efficacy of the levonorgestrel intrauterine system in treating menorrhagia: Actualities and ambiguities. J Family Plann Reprod Health Care 2002, 28: 99-100.
70. Singer, A., Ikomi, A. The use of a levonorgestrel-releasing intrauterine device in reduction of withdrawal bleeding in menopausal women with uterine fibroids. Pract Cases Menop 1998, 3: 18-9.
71. Starczewski, A., Iwanicki, M. Intrauterine therapy with levonorgestrel releasing IUD of women with hypermenorrhea secondary to uterine fibroids (Polish). Ginekol Polska 2000, 71: 1221-5.